TOP > 外国特許検索 > SOLID SUPPORT CONTAINING IGG-BINDING PEPTIDE, AND METHOD FOR SEPARATING IGG

SOLID SUPPORT CONTAINING IGG-BINDING PEPTIDE, AND METHOD FOR SEPARATING IGG

外国特許コード F180009466
整理番号 (S2017-0101-N0)
掲載日 2018年7月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP041404
国際公開番号 WO 2018092867
国際出願日 平成29年11月17日(2017.11.17)
国際公開日 平成30年5月24日(2018.5.24)
優先権データ
  • 特願2016-225483 (2016.11.18) JP
発明の名称 (英語) SOLID SUPPORT CONTAINING IGG-BINDING PEPTIDE, AND METHOD FOR SEPARATING IGG
発明の概要(英語) The present invention addresses the problem of: providing an IgG-binding peptide which can be used for the purification of an IgG and has excellent stability, e.g., alkali stability; and others. The present invention also addresses the problem of providing: a method for purifying an IgG using the IgG-binding peptide; and others. More specifically, the present invention relates to: a solid support containing an IgG-binding peptide; an IgG separation column including the solid support; a kit including the solid support or the column; a method for purifying an IgG using the solid support or the column; and others.
特許請求の範囲(英語) [claim1]
1. Wherein the human IgG is capable of binding a peptide immobilized in the solid-phase support, wherein the peptide is, according to the following equation I: (X1-3) -C-(X2) -H-(Xaa1) -G-(Xaa2) -L-V-W-C-(X1-3) (I) (in the formula, each of the X independently of any other cysteine amino acid residues, and which is a cysteine residue C, histidine residues H, which is an arginine residue Xaa1, lysine residues, leucine, asparagine residue or, or derivatives thereof, and g is glycine residue, glutamic acid or an asparagine residue Xaa2 and, leucine residue L, valine residue V, and tryptophan residues W.) Represented by a, comprises the amino acid sequence consisting of the amino acid residues 13-17, and 2 of the outside of the peptide in the two cysteine residues of a sulfide group, according to the following equation:
represented by a linker selected from the group consisting of a linker coupled by, R here is, substituted or not substituted with C1-C6 alkyl, the solid-phase support.
[claim2]
2. Wherein the peptide, the following formula II: (X1-3) -C-(Xaa3) -(Xaa4) -H-(Xaa1) -G-(Xaa2) -L-V-W-C-(X1-3) (II) (in the formula, each of the X independently of any other cysteine amino acid residues, and which is a cysteine residue C, histidine residues H, which is an arginine residue Xaa1, lysine residues, a leucine residue, or an asparagine residue, or derivatives thereof, and g is glycine residue, glutamic acid or an asparagine residue Xaa2 and, leucine residue L, valine residue V, tryptophan residues W, can be an alanine residue Xaa3, serine or threonine residue and the residue, and tyrosine residue Xaa4 residue or tryptophan.) Represented by a, comprising the amino acid sequence consisting of the amino acid residues 13-17, according to claim 1 through the solid phase carrier.
[claim3]
3. Wherein the peptide, the following formula III: (X1-3) -C-A-Y-H-(Xaa1) -G-E-L-V-W-C-(X1-3) (III) (in the formula, each of the non-cysteine X independently any of the amino acids residues, which is a cysteine residue and C, A is alanine residue, tyrosine residue Y, histidine residues H, which is an arginine residue Xaa1, lysine residues, a leucine residue, or an asparagine residue, or a derivative thereof and, and g is glycine residue, glutamic acid residue E, leucine residue L, valine residue V, W and tryptophan residues.) Represented by a, comprising the amino acid sequence consisting of the amino acid residues 13-17, according to claim 1 or 2 through the solid phase carrier.
[claim4]
4. 17 In the case where the amino acid residues, 1-3 from the end of the peptide N, for each of the amino acid residues 15-17, 1=S amino acid residue, g, or F, 2 amino acid residues without=D, g, A, S, P, homocysteine, or, 3 amino acid residues without=S, D, T, N, or R E, =S 15 amino acid residues, T D or, amino acid residues 16=H, g, Y, T, N, D, F, homocysteine, or, not, =Y 17 amino acid residues, F, H, M or, has no, any one of claims 1-3 in the solid phase carrier.
[claim5]
5. Wherein the peptide, the following 1) -14) of any one of the amino acid sequence that is, however, which is an arginine residue Xaa1, lysine residues, a leucine residue, or an asparagine residue, or derivatives thereof, is homocyste Xaa2 is, the solid-phase support according to claim 4: sequence SEQ ID NO:2) 3) RCAYH(Xaa1) GELVWCS ( 1) 2) GPDCAYH(Xaa1) GELVWCTFH ( 1) DCAYH(Xaa1) GELVWCT ( 3) 4) GPRCAYH(Xaa1) GELVWCSFH( sequence SEQ ID NO:4) 5) SPDCAYH(Xaa1) GELVWCTFH ( 7) 8) GPDCAYH(Xaa1) GELVWCSFH ( 6) 7) GPSCAYH(Xaa1) GELVWCTFH ( 5) 6) GDDCAYH(Xaa1) GELVWCTFH( sequence SEQ ID NO sequence SEQ ID NO:8) 9) GPDCAYH(Xaa1) GELVWCTHH ( 9) 10) GPDCAYH(Xaa1) GELVWCTFY( sequence SEQ ID NO:12) 13) RGNCAYH(Xaa1) GQLVWCTYH ( 13) 14) G(Xaa2) DCAYH(Xaa1) GELVWCT(Xaa2) H ( 10) 11) SPDCAYH(Xaa1) GELVWCTFY ( 11) 12) SDDCAYH(Xaa1) GELVWCTFY( sequence SEQ ID NO sequence SEQ ID NO:14).
[claim6]
6. Wherein the peptide, the following formula IV: (IV) D-C-(Xaa3) -(Xaa4) -H-(Xaa1) -G-(Xaa2) -L-V-W-C-T(in the formula, aspartic acid residue D, which is a cysteine residue and C, histidine residues H, which is an arginine residue Xaa1, lysine residues, a leucine residue, or an asparagine residue, or derivatives thereof, and g is glycine residue, glutamic acid or an asparagine residue Xaa2 and, leucine residue L, valine residue V, tryptophan residues W, is threonine residue T, Xaa3 alanine residue or threonine residue is, and, tyrosine residue Xaa4 residue or tryptophan.) Represented by a, an amino acid sequence comprising 13 amino acid residues, the solid-phase support according to claim 1 or 2.
[claim7]
7. Wherein the peptide, the following 1) -4) of any one of the amino acid sequence, however, which is an arginine residue Xaa1, lysine residues, a leucine residue, or an asparagine residue, or a derivative thereof, the solid-phase support according to claim 6: 1) DCTYH(Xaa1) GNLVWCT ( 16) 3) DCTYH(Xaa1) GELVWCT ( 17) 4) DCAWH(Xaa1) GELVWCT ( 15) 2) DCAYH(Xaa1) GNLVWCT( sequence SEQ ID NO:18 sequence SEQ ID NO).
[claim8]
8. Wherein the human IgG is capable of binding a peptide immobilized in a solid phase carrier, the peptide, the following formula V: D-C-(Xaa2) -(Xaa3) -(Xaa4) -(Xaa1) -G-(Xaa5) -L-(Xaa6) -W-C-T(V) (in the formula, aspartic acid residue D, which is a cysteine residue and C, glycine residue g, leucine residue L, tryptophan residues W, is threonine residue T, which is an arginine residue Xaa1, lysine residues, a leucine residue, or an asparagine residue, or derivatives thereof, alanine residue Xaa2 is, threonine or serine residue residues, tryptophan residues Xaa3 or tyrosine residue and, histidine residues Xaa4, arginine residue, serine residue or threonine residue, a glutamic acid residue is Xaa5, asparagine residue, an arginine residue, or an aspartic acid residue and, isoleucine residues or valine residue Xaa6 and in) are represented by, 13 amino acid residues comprising the amino acid sequence, and wherein 2 of the outside of the peptides in the two cysteine residues of a sulfide group, according to the following equation:represented by a linker selected from the group consisting of a linker coupled by, R here is, substituted or not substituted with C1-C6 alkyl, the solid-phase support.
[claim9]
9. Xaa1 an arginine residue, lysine residues or its acylating derivatives, or a leucine residue, any one of claims 1-8 the solid phase carrier.
[claim10]
10. Wherein the peptide, amino acid sequence of the following, the solid-phase support according to claim 1: GPDCAYHRGELVWCTFH (SEQ ID NO:31).
[claim11]
11. The linker,linker is represented, according to any one of claims 1-10 solid-phase support.
[claim12]
12. N PEG terminus of the peptide Iconified, according to any one of claims 1-11 solid-phase carrier.
[claim13]
13. C of peptide amide XhGREEK Iconified, according to any one of claims 1-12 solid-phase carrier.
[claim14]
14. Wherein the peptide multimers Iconified, according to any one of claims 1-13 solid-phase support.
[claim15]
15. The multimers peptide, the peptide having a spacer is disposed between, the solid-phase support according to claim 14.
[claim16]
16. Wherein the peptide having a spacer is disposed between the solid phase, to any one of claims 1-15 the solid phase carrier.
[claim17]
17. Any one of claims 1-16 of solid phase carriers, IgG separation column.
[claim18]
18. Any one of claims 1-16 of according to claim 17 IgG or a solid phase carrier including the separation columns, IgG for purification of the kit.
[claim19]
19. Claims 1-16 according to any one of the solid-phase support of the separation columns according to claim 17 IgG or IgG binding, and binding IgG IgG is eluted through which comprises the step of recovering, the purification method IgG.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • DAICEL CORPORATION
  • 発明者(英語)
  • ITO YUJI
  • UCHIMURA SEIICHI
国際特許分類(IPC)
指定国 (WO201892867)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close